Q1 2025 X4 Pharmaceuticals Inc Earnings Call Transcript

May 1, 2025 / 12:30 PM GMT

Release Date Price: €4.9

Transcript 10-Q8-K

Key Points

Positve

X4 Pharmaceuticals Inc (XFOR) has made significant progress in the development of Maverick 4 for chronic neutropenia, with over 90% of global trial sites activated.
The company has received a notice of allowance from the US Patent Office for Maverick 4, with the patent expected to expire in March 2041.
X4 Pharmaceuticals Inc (XFOR) reported cumulative sales of $3.5 million for Zoremby since its launch, indicating growing demand.
The company has secured international partnerships to expand the reach of Maverick 4 in Europe, Australia, New Zealand, and the MENA region.
X4 Pharmaceuticals Inc (XFOR) ended the first quarter of 2025 with nearly $90 million in cash, providing financial stability into the first half of 2026.

Negative

Sales for the first quarter were slightly lower than the previous quarter due to fluctuations in inventory resupply.
The company is still in the early stages of commercialization for Zoremby, with some sales volatility expected.
X4 Pharmaceuticals Inc (XFOR) had significant R&D and SG&A expenses, totaling $18.5 million and $15 million respectively for the first quarter.
The company had to implement a 1 for 30 reverse stock split to address NASDAQ listing rule deficiencies.
There is a high unmet need in the chronic neutropenia market, with approximately 15,000 individuals in the US still experiencing health challenges despite available treatments.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

XFOR.OQ - X4 Pharmaceuticals Inc
Q1 2025 X4 Pharmaceuticals Inc Earnings Call
May 01, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the X4 Pharmaceuticals first quarter 2025 Financial and operating results conference call.

At this time, all participants are in a listen-only mode.

A question and answer session will follow the formal presentation.

As a reminder, this conference call is being recorded.

It is now my pleasure to introduce your host, Dan Ferry from Lifeite Advisors. Please begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you operator good morning everyone.

Presenting on today's call will be ex-Force Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.